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Abstract
SLC11A1 is known to link infections, autoimmunity and cancers. A review is
presented of the mechanisms by which a balance is maintained between infections
caused by pathogens (viral, bacterial and protozoan; intracellular and extracellu-
lar) and disorders resulting from (acute or chronic) inﬂammation, and of the
interactions that determine how the initial innate immune system directs
subsequent acquired immune responses in human populations
This review discusses the role of the solute carrier family
11 member 1 protein (SLC11A1), formerly NRAMP1 (for
natural resistance associated macrophage protein 1), in
linking infections, autoimmunity and cancer. Chronic
inﬂammation is caused by a variety of factors including
bacterial, viral and parasitic infections, chemical irritants
and nondigestible particles. Chronic inﬂammation is asso-
ciated with a predisposition to cancer and autoimmunity
because the longer the inﬂammation persists, the higher the
risk of associated autoimmunity and carcinogenesis.
Immune cells involved in inﬂammation include leucocytes
such as neutrophils, monocytes, macrophages and eosino-
phils. These cells provide the soluble factors that are thought
to mediate the development of inﬂammation. When inﬂam-
mation goes unchecked it often leads to chronic inﬂamma-
tion-associated diseases. Slc11a1 in mice encodes a polytopic
integral 10–12 transmembrane protein, which is expressed
exclusively in macrophages and polymorphonuclear leuko-
cytes and neurons (Evans et al., 2001). Slc11a1 exacts
pleiotropic effects on macrophage function that include
enhanced chemokine KC, tumor necrosis factor-a, interleu-
kin-1b, inducible nitric oxide synthase and MHC class II
expression; all are important in the induction and main-
tenance of autoimmunity and cancer but also are crucially
important in resistance to intramacrophage pathogens such
as tuberculosis.
The protein is localized to the acidic endosomal and
lysosomal compartment of the macrophage (Searle et al.,
1998). In resting macrophages, slc11a1 resides within the
phagolysosome, but upon activation of the macrophage
slc11a1 translocates to the membrane of the phagolysosme
and serves as a divalent metal cation transporter regulating
and regulated by cellular iron (fe
21) levels (Atkinson &
Barton, 1988; Atkinson et al., 1997). Under normal physio-
logical conditions, slc11a1 delivers bivalent metal cations
from the cytosol into acidic late endosomal and lysosomal
compartment where the Fenton/and or Haber–Weiss reac-
tions generate toxic antimicrobial radicals for direct anti-
microbial activity against phagocytosed microorganisms
(Goswami et al., 2001). Prolonged accumulation of toxic
radicals can, however, have detrimental effects, causing cell
or tissue damage and contributing to the development
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autoimmunity. Toxic radicals generated as a result of
macrophage activation in response to stimuli are reactive
oxygen (generically referred to as oxidants: superoxide,
hydrogen peroxide, hypochlorous acid, singlet oxygen, and
the hydroxyl radical) and nitrogen (nitric oxide by the
inducible nitric oxide synthase) intermediates (Schumacker,
2006). Exogenous and endogenous agents that mediate
inﬂammation by activating the macrophage can cause
slc11a1 to translocate to the membrane of the phagoly-
sosome, where it serves as a cation transporter. Activated
macrophage-derived hydrogen peroxide may come into
contact with transition metals transported by slc11a1 into
lysosome or on DNA/RNA in the late endosomal compart-
ments or maydiffuse into the nucleus, forming a radical and
giving rise to the strand breaks and base modiﬁcations that
eventually lead to preneoplastic alterations (Storz, 2005).
Thus, slc11a1 functions to transport metal ions from high
(cytoplasmic) to low (intravascular) pH.
It is possible that the signiﬁcant increase in iron
deposition observed in the synovial membrane of rheuma-
toid arthritis patients, and foam cells in atherosclerotic
lesions, may be attributable to SLC11A1. SLC11A1 might
contribute to the pathogenesis of human systemic lupus
erythematosus, because particulate auto-antigens containing
nucleic acid and proteins released from dying or damaged
cells can be recognized by B cells that have been TLR 3, 7, 8,
and 9-activated and differentiated into antibody-producing
plasma cells (Leadbetter et al., 2002; Rifkin et al., 2005). In
mice, slc11a1-positive phagosomes during Mycobacterim
bovis infection are signiﬁcantly more acidic than those
formed in slc11a1-negative ones (Hackam et al., 1998).
The SLC11A1 gene, located on human chromosome
2q35, is c. 14kb in length and contains 15 exons. In humans,
a microsatellite polymorphism with a Z-DNA-forming
dinucleotide repeat in the 50 terminal region of the SLC11A1
is associated with infections, (ranging from viral to proto-
zoan; Shaw et al., 1997; Bellamy et al., 1988; Marquet et al.,
1999; Cervino et al., 2000; Gao et al., 2000; Meisner et al.,
2001; Awomoyi et al., 2002; Ryu et al., 2002; Liu et al., 2004;
Mohammed et al., 2004; Shaw et al., 1997), autoimmunity
(such as Kawasaki disease, sacoidosis, juvenile rheumatoid
arthritis, rheumatoid arthritis, inﬂammatory bowel disease
(IBD)), and diabetes; most of these diseases are thought to
have a microbial origin; (Hofmeister et al., 1997; Maliarik
et al., 2000; Sanjeevi et al., 2000; Singal et al., 2000; Yang
et al., 2000; Kojima et al., 2001; Ouchi et al., 2003) multiple
sclerosis (Kotze et al., 2001) and more recently with esopha-
geal cancer in a South African coloured population (Zaahl
et al., 2005).
Examination of the pattern of genetic diversity at eight
microsatellite markers within a 3-Mb region ﬂanking the
SLC11A1 locus across geographically diverse human popu-
lations has provided evidence for genetic differences at the
SLC11A1 locus in 21 global human populations (Awomoyi
& Tishkoff, unpublished data).
Because SLC11A1, protein translocates to the membrane
of the late endocytic/lysosomal compartment upon activa-
tion of the macrophage (Gruenheid et al., 1997), serves as an
antiporter ﬂuxing cations in either direction of the mem-
brane (Goswami et al., 2001), namely into the phagolyso-
some or into the cytosol depending on the pH gradient, it
should inﬂuence the assembly of the inﬂammasome com-
plex and affect the ability of the macrophage to secrete
pro-inﬂammatory interleukin (IL)-1b and IL-18. It should
inﬂuence antiviral responses mediated by the cytosolic
helicases RIG-I (for retinoic acid-inducible protein I) and
MDA5 (for melanoma differentiation-associated protein 5).
Apart from being involved in inﬂammatory activities,
SLC11A1 might inﬂuence apoptotic processes by regulating
the function of cytosolic nucleotide – oligomerization
domains (NODs), a group of proteins of which cryopyrin,
a constituent of the inﬂamasome complex, is a member.
Loss or gain of function of the NOD proteins is associated
with several disregulated immune response disorders
(Masumoto & Inohara, 2005). Transcriptional activation of
SLC11A1 should lead to apoptosis, in accordance with the
notion that genes that deplete the iron content of the cell
cytosol antagonize cell growth. By contrast, transcriptional
repression of SLC11A1 could lead to cell survival. SLC11A1
might inﬂuence immune responses to viral vector delivery
systems (Thorsen et al., 2006; Xu et al., 2006; Zhang &
Godbey, 2006), for example herpes virus vector delivery
system for CpG, adenovirus vectors double-stranded RNA,
retroviral vectors; single-stranded RNA, adenovirus asso-
ciated viral vectors single-stranded DNA and baculoviral
vectors, by regulating antigen processing and the activity of
proteases in the late endosomal compartment.
Finally, intracellular bacteria such as attenuated strains of
Salmonella typhimurium are widely used as vehicles for
delivery and expression of vaccine antigens in infectious
(Soo et al., 1998) and noninfectious disease models (Barnett
et al., 2005; Kalvakolanu DV, pers. commun., unpublished
information). In mice, early control of bacterial replication
following infection with S. typhimurium is controlled by
slc11a1. SLC11A1 might inﬂuence the responses to such
recombinant bacteria vaccines in multiple ways, by, for
example, regulation of bacterial load or recombinant anti-
gen dose, class II molecule expression, costimulatory or
adjuvant activity, or antigen processing by regulation of the
activity of proteases in the late endosomal compartment.
Results in congenic mice using live attenuated S. typhimur-
ium aroA aroD mutants carrying recombinants antigen
tetanus toxoid, and leishmanial gp63 showed that wild-type
S. typhimurium-resistant mice mounted a predominantly
Th1-type response to vaccination, whereas mutant mice
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1997; Soo et al., 1998). Analogous to this in humans are the
two predominant SLC11A1 (GT)n Z-DNA promoter alleles,
namely allele 2 and allele 3. These alleles are reported to
account for opposing levels of SLC11A1 gene expression: the
allele t(gt)5 ac (gt)5 ac (gt)9 g (also known as allele 3) drives
high gene expression, while the allele t(gt)5 ac (gt)5 ac (gt)10
g (also known as allele 2) drives low gene expression (Searle
& Blackwell, 1999). In addition, the allele that drives high
gene expression is associated with autoimmunity and cancer
but protects against infectious diseases, whereas the one that
drives low expression is associated with infections such as
tuberculosis but protects against autoimmunity and cancer.
These observations suggest that chronic hyperactivation of
macrophages associated with allele 3 is functionally linked
to cancer and autoimmune disease susceptibility, while the
poor level of SLC11A1 expression promoted by allele 2
contributes to infectious disease susceptibility.
A summary of the distribution of these alleles based on
genotyping shows that, whereas the level of distribution of
allele 2 is c. 0.176% in the Nigerian population and 0.104%
intheGambian population,it is a littlehigher in East African
and non-African populations: c. 0.268% in the Tanzanian
population, c. 0.24% in the Lebanese population, 0.3% in
European populations, and 0.265% in New World popula-
tions. The level in the Chinese population (Awomoyi &
Tishkoff, unpublished data), at 0.1%, is similar to that in
the African populations (Table 1). Allele 2 is the intracellular
infection susceptibility allele. It could be the case that in
endemic infectious disease populations the protective allele 3
is maintained atahigher frequency.Giventheimportantrole
of this gene as a cation antiporter inﬂuencing macrophage
function, it can be speculated that, in humans, populations
with genetic differences in haplotype structure and linkage
disequilibrium (LD) patterns will exhibit altered susceptibil-
ity to disease and will respond differently to infections and
therapy, whether curative or prophylactic. This could impact
greatly on vaccine delivery and efﬁcacy (Awomoyi & Tishk-
off, unpublished data).
Recent reports show that it is the type and concentrations
of immuno-modulators present at the site of infection that
determine the outcome of infection. For example, upon
macrophage activation the presence of IL-6 alone (Rochman
et al., 2005), IL-6 together with TGF-beta (Veldhoen et al.,
2006a,b), or TGF-beta alone (Marie et al., 2002) should
determine which type of T-helper acquired immune cells are
activated. Induction of IL-6 alone is shown to promote the
production of prostaglandins, which are important in the
generation of oxidative radicals (Rochman et al., 2005). IL-6
produced in combination with TGF-beta is important in
driving the differentiation of naive T cells to the pro-
inﬂammatory T-helper 17 phenotype that produces IL-17
(Veldhoen et al., 2006a,b). IL-17 is associated with chronic
inﬂammation and therefore autoimmunity in several
Table 1. Distribution of SLC11A1 Z-DNA promoter alleles in global human populations
Population
Chromosome
numbers (2n) Allele 1 Allele 2 Allele 3
Geographic/country
region Geographic region allele frequency
Wollof 24 2 (0.085) 2 (0.085) 20(0.83) The Gambia
Mandinka 54 1 (0.02) 2 (0.04) 51 (0.94) Allele 1: 0.053, 2: 0.104, 3: 0.843.
Gambian/other 48 2 (0.05) 5 (0.01) 41 (0.85)
Fula 34 2 (0.06) 5 (0.015) 27 (0.79)
Igala 46 5 (0.11) 41 (0.89) Nigeria
Bassange 28 7 (0.25) 21 (0.75)
Ibo 52 6 (0.12) 46 (0.88) Allele 1: 0.005, 2: 0.176, 3: 0.819.
Fulani 40 9 (0.225) 31 (0.775)
Koma 94 17 (0.18) 77 (0.82)
Yoruba 106 3 (0.03) 18 (0.17) 85 (0.801)
Malawians1 2542 48 (0.019) 524 (0.206) 1970 (0.775) Malawi Allele 1: 0.019, 2: 0.206, 3: 0.775
Burunge 38 9 (0.24) 29 (0.76) Tanzania
Hadza 42 7 (0.17) 35 (0.83)
Maasai 46 16 (0.35) 30 (0.65) Allele 2: 0.268, 3: 0.732.
Sandawe 50 17 (0.34) 33 (0.66)
Turu 38 9 (0.24) 29 (0.76)
South Africans 1284 11 (0.008) 361 (0.281) 912 (0.71) South African Caucasians Allele 5: 0.008, 2: 0.281, 3: 0.71
Lebanesse 68 1 (0.02) 16 (0.24) 51 (0.75) Europe/Middle East/Asia
N. Europe 20 8 (0.4) 12 (0.6) Allele 1: 0.002, 2: 0.235, 3: 0.763
Russian 20 4 (0.2) 16 (0.8)
Chinese 20 2 (0.1) 18 (0.9)
San Martin 50 12 (0.24) 38 (0.76) New World Allele 1: 0.01, 2: 0.265, 3: 0.725
Quechua 48 1(0.02) 14 (0.29) 33 (0.69)
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anti-inﬂammatory forkhead box protein (foxp)-3 expres-
sing regulatory T cells (FOXP) 3
1Tregs in the periphery
(Marie et al., 2002).
Another class of T regulatory cells that lack the Fox3p
develops under the control of persistently high levels of IL-10
(Groux et al., 1997). This class of low proliferative T
regulatory cells suppress antigen–speciﬁc responses and ac-
tively down regulate a pathological immune response in vivo.
In our previous study we showed that allele 2 of the SLC11A1
promoter gene polymorphism inﬂuences IL-10 production
and individuals with active TB produce higher levels IL-10
even after recovery from TB in relations to ethnically
matched age and gender controls (Awomoyi et al., 2002).
Agents that activate macrophage together with host
SLC11A1 alleles will exert different effects on SLC11A1
function, but how SLC11A1 functions help determine the
outcome of infection by modulating the production of these
cytokines in not known. Comparative analysis of the
SLC11A1 genomic region in nonhuman and human primates
reveals a protein with a highly conserved amino-acid se-
quence across species but with striking nucleotide differences
at the 50 and 30 untranslated regions (UTRs) and within
intronic regions, thus suggesting that this gene might be
differentially regulated in different species. One major differ-
ence at this locus between species includes the type and
locations of transcription factor binding sites in the 50UTR
of SLC11A1. Of particular importance is the binding site for
theactivating transcription factor-3(ATF-3; also known as an
AP-1-like element, Lee et al., 2000) adjacent to the 50
sequence of the Z-DNA-forming microsatellite polymorph-
isminhumans,whichisnotfoundinmice.Figure 1showsan
alignment of portions of the SLC11A1 50 promoter genomic
region in ﬁve mammals, demonstrating that, whereas a
TGACTCT ATF-3 putative binding site is present in Homo
sapiens, Pan troglodytes and Macaca mulatta, this sequence is
absent in Mus musculus.I nRattus norvegicus and Pongo
pygmaeus, the second cytosine is replaced by a thymine.
ATF-3 is a negative regulator of TLR4 (Gilchrist et al., 2006).
ATF-3 can heterodimerize with Jun proteins to activate
transcription. By contrast, the homodimer ATF-3 on its own
is a repressor of transcription when bound to DNA. ATF-3 is
a member of the ATF/CREB family of basic leucine zipper (b-
zip)-type transcription factors, and its expression is increased
by various pathophysiological conditions and in several
cancer cells (Hai et al., 1999). The expression of ATF-3 is
relatively low in most cell types under normal conditions but
is strongly induced in response to many environmental
changes as an immediate early-response gene. This B-DNA-
forming sequence motif is found in the promoter of rat
tumor suppressor gene (p53) (Lee et al., 2000; Kawauchi
et al., 2002; Yau et al., 2002) and human transforming growth
factor beta(TGF-b)gene(Owen& Ostrowski,1990),where it
has been demonstratedtobe biologicallyactive.Similarly, it is
adjacent to the 50 promoter Z-DNA-forming microsatellite
repeat polymorphism in SLC11A1 but it is unclear whether it
is an active ATF-3 binding site in SLC11A1. The formation of
Z-DNA structure is known to play an active role in modulat-
ing inhibitory chromatin structure (Ha et al., 2005; Liu et al.,
2006). Should the ATF-3 binding site be a transcriptional
active site in the promoter of SLC11A1, carriage of different
alleles interrupted by mutations at the adjacent Z-DNA
microsatellite repeat may inﬂuence chromatin remodelling
and accessibility of transcription factors. We can speculate
that, under normal physiological conditions, when the
homodimer ATF-3 binds to this target sequence in the 50
promoter region of SLC11A1 it should repress transcriptional
activation of SLC11A1; conversely, heterodimerization of
ATF3 with other transacting factors should promote tran-
scriptional activation of SLC11A1.
Fig. 1. Alignment of the 50 promoter region
of SLC11A1 in ﬁve mammalian species.
Alignment of Homo sapiens; GenBank accession
number AF229163, Pan troglodytes; ensembl,
Macaca mulatta; XM_001089328, mouse;
GenBank accession number NM_013612, &
Rattus norvegicus; ensembl).
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leads to apoptosis and cell death while transcriptional
repression of SLC11A1 leads to cell proliferation and survi-
val if unchecked could result in cancer and autoimmunity.
The ATF-3 putative site in the promoter of SLC11A1 along
with other transacting factors might have a regulatory role
in modulating the effects of SLC11A1. This review has thus
highlighted some of the mechanisms by which SLC11A1
might be mediating, inﬂuencing or modulating the outcome
of these diseases and disorders in human populations.
Statement
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